Share Rs. 24.15 per equity share was bought, compared to Friday’s close of Rs. There was a 1.5% premium over the closing price of 23.78.
Kedia bought the shares through his investment company Kedia Securities Private Limited.
Mangalam Drugs shares are up 5% today or Rs. 1.18 to Rs. 24.96, which was also the stock’s high of the day.
Following the bulk deal, the shares traded at Rs. bounced off a 52-week low of 22.80.
Mangalam Drugs share Rs. 80% down from 52-week high of 124.89.
The market capitalization of the company is Rs. 39.51 crores.
Also Read: Honasa Consumer Block Deal: Promoter Varun Alag raises stake in MamaEarth parent as stock trades 15% below IPO price
Mangalam Drugs & Organics started manufacturing Active Pharmaceutical Ingredients (APIs) and Intermediates in 1977 at Vapi-Gujarat. It has multi-product manufacturing facilities at two locations, and an in-house research and development laboratory accredited by the Government of Scientific and Indus, Delhi. The company is known for its anti-malarial API.
In the year-ago period, the company made Rs. 2.7 crore as against a net profit of Rs. 7.4 crore reported a consolidated net loss. Its total revenue also fell by 38% in the quarter under review to Rs. 50 crore as against Rs. 80 crore, according to Trendlyne data.
Also Read: John Cockerill Bulk Deal: Ramesh Damani Rs. 13 crore buys the stake as the promoter pays Rs. 91 crores
The stock has been highly volatile with a 1-year beta hovering around 1.2, Trendline data shows.
(Disclaimer: Recommendations, suggestions, opinions and views given by experts are their own. These do not represent the views of Economic Times.)
(You can now subscribe to our ETMarkets WhatsApp channel)